pharminent

• News

GSK Licenses a Preclinical Trispecific T Cell Engager From China’s Chimagen for Up to $750M in Myeloma

pharminent September 15, 2026

• News

Scholar Rock’s Isemblyd Wins First Muscle-Targeted SMA Approval — at $310,000 With a Fracture Warning

pharminent September 14, 2026

• News

FDA Oncology Chief Sets Out His Agenda — and Narrows the Etcamah Precedent

pharminent September 11, 2026

• News

Bayer’s Hyrnuo Wins Accelerated Frontline Approval in HER2-Mutant NSCLC, Seven Months Behind Boehringer

pharminent September 10, 2026

• Regulatory

Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion

pharminent September 10, 2026

• Regulatory

HHS appoints permanent FDA CBER, CDER heads

pharminent September 10, 2026

• M&A / Deals

Solstice Oncology secures $225m to drive porustobart’s development for cancer

pharminent September 10, 2026

• News

FDA Names Permanent CDER and CBER Directors While the Commissioner’s Post Awaits Confirmation

pharminent September 9, 2026

• Manufacturing

Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision

pharminent September 9, 2026

• News

Novartis’s Del-Desiran Misses Primary Endpoint in HARBOR, Putting the $12B Avidity Deal Under Scrutiny

pharminent September 8, 2026

• News

Novartis and Ionis’ Pelacarsen Lowers Lp(a) but Misses on Cardiovascular Outcomes

pharminent September 7, 2026

• M&A / Deals

UK’s Claret Capital raises 575m for European biotechs

pharminent September 7, 2026

• Clinical Data

Novartis hit as Lp(a) drug fails cardio outcomes trial

pharminent September 7, 2026

• Regulatory

FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer

pharminent September 7, 2026

• Clinical Data

Major trial of Roche Alzheimer’s drug kicks off in Europe

pharminent September 7, 2026

• News

Ionis Wins First-Ever FDA Approval for Alexander Disease with Zanvastro

pharminent September 4, 2026

• Clinical Data

AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study

pharminent September 4, 2026

• Regulatory

Ionis nets Zanvastro US approval in first for Alexander disease

pharminent September 4, 2026

• News

Ivonescimab Beats Keytruda on Survival in China-Only Trial as Its Global Study Stumbles

pharminent September 3, 2026

• M&A / Deals

GSK wagers up to $1.3B on a different kind of cancer drug

pharminent September 3, 2026

• Clinical Data

Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial–again

pharminent September 3, 2026

• M&A / Deals

Boehringer signs AI drug discovery deal with Owkin

pharminent September 3, 2026

• M&A / Deals

Novartis signs $3.2bn drug delivery deal with Alteogen

pharminent September 3, 2026

• News

UK Suspends Amgen’s Tavneos for New Patients as a Data-Integrity Cascade Spreads Across Three Regulators

pharminent September 2, 2026

• Clinical Data

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

pharminent September 2, 2026

• Pipeline

Beyond GLP1s: The race for nextgen obesity drugs starts in the preclinical models

pharminent September 2, 2026

• Market Access

Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing

pharminent September 2, 2026

• M&A / Deals

Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology

pharminent September 2, 2026

• Manufacturing

US puts $125m into personalised RNA therapy production

pharminent September 2, 2026

• Other

Takeda and Weave Bio collaborate on AI-driven automation in drug development

pharminent September 2, 2026

• News

Novartis Posts Phase 3 MS Win and Halts Eight Autoimmune CAR-T Trials

pharminent September 1, 2026

• Policy / Pricing

Mid-cap biotechs join Trump’s latest round of drug pricing deals

pharminent September 1, 2026

• Clinical Data

Novartis says MS pill succeeds in two large studies

pharminent September 1, 2026

• News

Lilly Pays Up to $2.875 Billion for Merida and a Phase 1 Autoantibody Platform

pharminent August 31, 2026

• Regulatory

FDA OKs Takeda, Protagonist drug for rare blood cancer

pharminent August 31, 2026

• M&A / Deals

Lilly adds to immune drug pipeline with $2.9B Merida buyout

pharminent August 31, 2026

• Regulatory

FDA clears Takeda, Protagonist’s first-in-class PV drug

pharminent August 31, 2026

• Clinical Data

ESC 2026: Evolocumab explores new frontiers in CV disease prevention

pharminent August 31, 2026

• M&A / Deals

Acquisitive Lilly offers $2.88bn for Merida Bio

pharminent August 31, 2026

• News

FDA Approves Mounjaro Label Expansion to Reduce Cardiovascular Risk in Type 2 Diabetes

pharminent August 28, 2026